Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & Co., Inc.

Merck Animal Health

Merck Canada

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. 

This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

NGM Biopharmaceuticals

Just - Evotec Biologics

eASIC

SAB Biotherapeutics

Alnylam Pharmaceuticals

Hangzhou Just Biotherapeutics (Just China)

Sutro Biopharma

Themis Bioscience

Seagen

Private Capital Advisors

Gavi, the Vaccine Alliance

Merck

A diverse workforce is not only fundamental to our company's future success, but it's also a part of our rich history. 
 
🧬 Susan Jenkins paved the way for black women in science at Merck, as part of the team that first synthesized ribonuclease. She also served as a black university liaison in our company's corporate equal employment affairs department.
 
⚾️ After the integration of Major league Baseball, star pitcher, Jimmy Dean, famous for his sinker-ball found a second career at Merck until retiring from his position as a technical analyst in 1990.
 
👥 In 1968, Merck appointed Lawrence “Larry” Branch vice president of personnel relations, responsible for employment, training and promotion of persons from all minority groups. This new position marked the beginnings of Merck’s Office of Equal Employment Affairs — one of the first in the country to prioritize equity for black employees.
 
We remain committed to attracting and developing diverse talent during #BlackHistoryMonth and every day. Check out open roles to join our team: http://merck.us/49Qmxqe

Wife, mother, and employee, Gina Esposito, MSM-HC, had 20 years of normal cervical screenings before she was diagnosed with HPV-related #cervical precancer. Today she feels empowered to share her story with colleagues and encourage others to take care of their health.

This #BlackHistoryMonth, we want to raise awareness of the importance of diversity in clinical trials and our ongoing efforts to increase participation from communities that have historically been underrepresented in research. Hear from Ashley C. Moultrie, director of diversity & community engagement, on why it should be prioritized and the positive impact it can have on our efforts to help achieve health equity.

Heart failure impacts more than 6 million Americans. Robin and Ray, active members with The Mended Hearts, Inc., are living with the condition. Watch to learn about their experiences.

We’re proud to be one of Fortune's World’s Most Admired Companies for 2024, ranking No. 3 in the pharmaceuticals industry for the second year in a row! We’re grateful for the ongoing dedication of our colleagues, whose support has enabled us to achieve this recognition. 

Interested in joining one of the #MostAdmiredCos? See open roles at our company: https://lnkd.in/eSABXQ3

Through mentorship, education, and representation, let's empower women to explore science and technology. In honor of this #IDWGS, we spoke to three scientists at our company about how mentorship is helping fuel the next generation of #WomenInScience.

We’re proud to be named No. 1 in the pharmaceuticals and biotech industry for the fourth year in a row and No. 25 overall on CNBC and JUST Capital’s list of America’s Most JUST Companies. See open roles at our company to join us in helping to create a safer, healthier and more sustainable world for people and communities everywhere: https://lnkd.in/eSABXQ3 #MostJUST

Today we announce the upcoming retirement of EVP and Chief Human Resources Officer Steve Mizell. Betty Larson, a leader with more than 20 years in health care and human resources, will become our EVP and CHRO effective April 8.

We’re following the science this #WorldCancerDay as we work to discover innovations that can help more people no matter what stage of cancer they have, or so they may never be diagnosed at all.

Rob Davis, chairman and CEO, on our Q4 and full-year 2023 #earnings: http://merck.us/3HJtT2M

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	44.03B -	42.24B 4.08%	39.50B 6.48%	39.81B 0.78%	40.12B 0.79%	42.29B 5.41%	46.84B 10.75%	47.99B 2.46%	48.70B 1.48%	59.28B 21.72%	59.87B 0.99%
cost of revenue	16.95B -	16.77B 1.10%	14.93B 10.94%	13.89B 6.98%	12.78B 8.03%	13.51B 5.75%	14.11B 4.46%	15.48B 9.73%	13.63B 12.01%	17.41B 27.78%	15.98B 8.24%
gross profit	27.08B -	25.47B 5.95%	24.56B 3.55%	25.92B 5.50%	27.35B 5.52%	28.79B 5.26%	32.73B 13.70%	32.51B 0.67%	35.08B 7.90%	41.87B 19.37%	43.89B 4.83%
selling and marketing expenses	11.91B -	11.61B 2.56%	10.31B 11.14%	9.76B 5.34%	9.83B 0.70%		1.90B -	1.80B 5.26%	2B 11.11%	2.20B 10%
general and administrative expenses						10.10B -	8.71B 13.73%	8.67B 0.54%	7.63B 11.93%	7.84B 2.72%
selling general and administrative expenses	11.91B -	11.61B 2.56%	10.31B 11.14%	9.76B 5.34%	9.83B 0.70%	10.10B 2.77%	10.62B 5.08%	10.47B 1.38%	9.63B 7.97%	10.04B 4.24%	10.38B 3.39%
research and development expenses	7.50B -	7.18B 4.30%	6.70B 6.63%	7.19B 7.31%	9.98B 38.75%	9.75B 2.30%	9.87B 1.23%	13.56B 37.34%	12.24B 9.68%	13.55B 10.64%	30.53B 125.35%
other expenses	12M -	12.00B 99,916.67%	-72M 100.60%	-357M 395.83%	304M 185.15%	849M 179.28%	-139M 116.37%	886M 737.41%	1.34B 51.35%	-1.50B 211.93%	345M 122.98%
cost and expenses	36.37B -	35.55B 2.24%	31.95B 10.13%	30.85B 3.46%	32.59B 5.64%	33.36B 2.38%	34.60B 3.70%	39.51B 14.20%	35.51B 10.14%	41.00B 15.48%	56.89B 38.75%
operating expenses	19.41B -	18.79B 3.23%	17.02B 9.42%	16.96B 0.36%	19.81B 16.84%	19.85B 0.21%	20.49B 3.19%	24.03B 17.27%	21.88B 8.94%	23.59B 7.82%	40.91B 73.43%
interest expense	801M -	732M 8.61%	672M 8.20%	693M 3.13%	754M 8.80%	772M 2.39%	893M 15.67%	831M 6.94%	806M 3.01%	962M 19.35%	1.15B 19.13%
ebitda	8.35B -	19.21B 130.17%	7.97B 58.51%	9.02B 13.15%	8.27B 8.33%	10.25B 24.00%	12.88B 25.65%	9.06B 29.65%	13.86B 52.96%	18.62B 34.34%	6.85B 63.19%
operating income	7.67B -	6.68B 12.81%	7.55B 12.93%	6.03B 20.10%	7.31B 21.21%	8.93B 22.19%	9.23B 3.31%	5.44B 41.09%	10.65B 95.84%	14.71B 38.17%	2.98B 79.73%
depreciation and amortization	6.99B -	6.69B 4.25%	6.38B 4.72%	5.44B 14.65%	4.64B 14.78%	4.52B 2.54%	3.65B 19.19%	3.63B 0.74%	3.21B 11.34%	3.91B 21.62%	3.87B 0.95%
total other income expenses net	-1.58B -	11.07B 799.05%	-1.76B 115.93%	-1.10B 37.83%	-419M 61.77%	199M 147.49%	2.24B 1,024.12%	3.35B 49.98%	3.23B 3.64%	1.73B 46.37%	-1.09B 163.03%
income before tax	5.54B -	17.28B 211.69%	5.40B 68.75%	7.50B 38.84%	6.75B 10.03%	8.70B 28.96%	11.46B 31.75%	8.79B 23.32%	13.88B 57.88%	16.44B 18.48%	1.89B 88.51%
income tax expense	1.03B -	5.35B 420.33%	942M 82.39%	1.79B 89.70%	4.16B 132.51%	2.51B 39.64%	1.69B 32.74%	1.71B 1.30%	1.52B 11.00%	1.92B 26.10%	1.51B 21.17%
net income	4.40B -	11.92B 170.66%	4.44B 62.73%	5.69B 28.12%	2.57B 54.88%	6.22B 142.21%	9.84B 58.25%	7.07B 28.20%	13.05B 84.65%	14.52B 11.27%	365M 97.49%
weighted average shs out	2.93B -	2.84B 3.05%	2.78B 2.01%	2.75B 1.16%	2.70B 1.90%	2.59B 3.86%	2.56B 1.06%	2.53B 1.36%	2.53B 0%	2.53B 0.08%	2.54B 0.20%
weighted average shs out dil	3.00B -	2.93B 2.27%	2.84B 2.97%	2.79B 1.90%	2.75B 1.40%	2.68B 2.51%	2.58B 3.70%	2.54B 1.51%	2.54B 0.12%	2.54B 0.16%	2.55B 0.20%
eps	1.50 -	4.20 180%	1.60 61.90%	2.07 29.37%	0.95 54.11%	2.40 152.63%	3.84 60%	2.79 27.34%	5.16 84.95%	5.73 11.05%	0.14 97.56%
epsdiluted	1.47 -	4.07 176.87%	1.56 61.67%	2.04 30.77%	0.93 54.41%	2.32 149.46%	3.82 64.66%	2.78 27.23%	5.14 84.89%	5.71 11.09%	0.14 97.55%

NYSE:MRK

Merck & Co., Inc. (MSD outside of the U.S. and Canada)

Last Close

125.85

26/07 20:00

Market Cap

322.43B

Beta: 0.35

Volume Today

4.76M

Avg: 7.72M

PE Ratio

69.75

PFCF: 24.38

Dividend Yield

2.34%

Payout:159.35%

Preview